Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Eli Lilly and Company
Pfizer
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Roswell Park Cancer Institute
Vejle Hospital
RemeGen Co., Ltd.
Pfizer
Institut du Cancer de Montpellier - Val d'Aurelle
National Cancer Institute (NCI)
Pfizer
Alliance for Clinical Trials in Oncology
UNICANCER
City of Hope Medical Center
First Affiliated Hospital of Guangxi Medical University
Ruijin Hospital
Institut Bergonié
IFOM ETS - The AIRC Institute of Molecular Oncology
First Affiliated Hospital of Guangxi Medical University
Memorial Sloan Kettering Cancer Center
Pfizer
Baylor College of Medicine
NRG Oncology
NuCana plc
Charite University, Berlin, Germany
Memorial Sloan Kettering Cancer Center
Sun Yat-sen University